NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $7.62 +0.04 (+0.53%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BioCryst Pharmaceuticals alerts: Email Address About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BCRX alerts:Sign Up Key Stats Today's Range$7.55▼$7.7650-Day Range$7.02▼$8.6952-Week Range$4.03▼$8.88Volume1.64 million shsAverage Volume3.11 million shsMarket Capitalization$1.57 billionP/E RatioN/ADividend YieldN/APrice Target$14.17Consensus RatingModerate Buy Company OverviewBioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More… WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW BioCryst Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks78th Percentile Overall ScoreBCRX MarketRank™: BioCryst Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 266th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioCryst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.38) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.78% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 1.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.85 Percentage of Shares Shorted11.78% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 1.08%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.18 News SentimentBioCryst Pharmaceuticals has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioCryst Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Stock News HeadlinesAnalysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $14.17September 23, 2024 | americanbankingnews.comBioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksSeptember 17, 2024 | globenewswire.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsThe stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.September 29, 2024 | Behind the Markets (Ad)BlackRock Inc. Expands Stake in BioCryst PharmaceuticalsSeptember 12, 2024 | finance.yahoo.comBioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumSeptember 6, 2024 | globenewswire.comBioCryst Appoints Dr. Donald Fong Chief Medical OfficerSeptember 5, 2024 | finance.yahoo.comBioCryst Pharma Appoints Donald Fong As New Chief Medical OfficerSeptember 5, 2024 | markets.businessinsider.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2024 | globenewswire.comSee More Headlines BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of the year. Since then, BCRX shares have increased by 27.2% and is now trading at $7.62. View the best growth stocks for 2024 here. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its earnings results on Monday, August, 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.11. BioCryst Pharmaceuticals's revenue for the quarter was up 34.9% compared to the same quarter last year. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX) and La Jolla Pharmaceutical (LJPC). Company Calendar Last Earnings8/05/2024Today9/29/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees530Year Founded1986Price Target and Rating Average Stock Price Target$14.17 High Stock Price Target$30.00 Low Stock Price Target$7.00 Potential Upside/Downside+85.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,540,000.00 Net Margins-38.18% Pretax Margin-38.33% Return on EquityN/A Return on Assets-28.14% Debt Debt-to-Equity RatioN/A Current Ratio2.82 Quick Ratio2.78 Sales & Book Value Annual Sales$382.24 million Price / Sales4.11 Cash FlowN/A Price / Cash FlowN/A Book Value($2.22) per share Price / Book-3.43Miscellaneous Outstanding Shares206,377,000Free Float196,471,000Market Cap$1.57 billion OptionableOptionable Beta1.88 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BCRX) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredThe only candlestick pattern worth a darnIt’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people thi...WealthPress | SponsoredHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buyi...Insiders Exposed | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.